Evaluation and management of patients with heart disease and cancer: Cardio-oncology

Mayo Clinic Proceedings

Volumn 89, Issue 9, 2014, Pages 1287-1306

  Herrmann, Joerg ^a   Lerman, Amir ^a   Sandhu, Nicole P ^a   Villarraga, Hector R ^a   Mulvagh, Sharon L ^a   Kohli, Manish ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALDOSTERONE ANTAGONIST; ALEMTUZUMAB; ALPHA2B INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BORTEZOMIB; BUSULFAN; CAPECITABINE; CISPLATIN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; LAPATINIB; MITOMYCIN; MITOXANTRONE; PENTOSTATIN; PERTUZUMAB; RAZOXANE; RETINOIC ACID; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGINA PECTORIS; ANUS CANCER; ANUS CARCINOMA; AORTA DISSECTION; ARTERIAL THROMBOEMBOLISM; ARTERY EMBOLISM; ARTERY THROMBOSIS; BLADDER CANCER; BRADYCARDIA; BRAIN ISCHEMIA; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARDIAC PATIENT; CARDIO ONCOLOGY; CARDIOLOGY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED CARDIOMYOPATHY; CHEMOTHERAPY INDUCED CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; COLON CANCER; COLORECTAL CANCER; COMORBIDITY; CORONARY ARTERY SPASM; CUTANEOUS T CELL LYMPHOMA; DIGESTIVE SYSTEM CANCER; DRUG MEGADOSE; EARLY DIAGNOSIS; ECG ABNORMALITY; ESOPHAGUS CANCER; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HEALTH CARE NEED; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HEPATOBILIARY SYSTEM CANCER; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; INFORMATION RETRIEVAL; KIDNEY CANCER; KIDNEY CARCINOMA; LIMB ISCHEMIA; LUNG CANCER; LUNG SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MEDLINE; MESENTERIC ISCHEMIA; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYELOPROLIFERATIVE DISORDER; MYOCARDITIS; NONHODGKIN LYMPHOMA; ONCOLOGY; OSTEOSARCOMA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PATIENT CARE; PATIENT MONITORING; PERICARDIAL EFFUSION; PERICARDITIS; POLYCYTHEMIA VERA; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; QT PROLONGATION; QUALITY OF LIFE; RADIATION INJURY; REVIEW; RISK ASSESSMENT; SARCOMA; SOFT TISSUE SARCOMA; STOMACH ADENOCARCINOMA; STOMACH CANCER; SUDDEN CARDIAC DEATH; SYSTEMIC THERAPY; TESTIS CANCER; THORAX PAIN; THROMBOCYTHEMIA; THROMBOSIS; THYMOMA; UTERINE CERVIX CANCER; VARIANT ANGINA PECTORIS; VASOSPASM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COMPLICATION; HEART DISEASES; NEOPLASMS;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HUMANS; NEOPLASMS; RISK ASSESSMENT;

EID: 84937774528     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2014.05.013     Document Type: Review

References (137)

1. C.K. Lee, D. Aeppli, and M.E. Nierengarten The need for long-term surveillance for patients treated with curative radiotherapy for Hodgkin's disease: University of Minnesota experience Int J Radiat Oncol Biol Phys 48 1 2000 169 179
2. C. Jaworski, J.A. Mariani, G. Wheeler, and D.M. Kaye Cardiac complications of thoracic irradiation J Am Coll Cardiol 61 23 2013 2319 2328
3. M. Aapro, C. Bernard-Marty, and E.G. Brain et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper Ann Oncol 22 2 2011 257 267
4. C. Serrano, J. Cortes, and L. De Mattos-Arruda et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors Ann Oncol 23 4 2012 897 902
5. L. Tarantini, S. Gori, P. Faggiano ICARO (Italian CARdio-Oncologic) Network Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a multicenter cohort analysis Ann Oncol 23 12 2012 3058 3063
6. D. Cardinale, A. Colombo, and G. Lamantia et al. Cardio-oncology: a new medical issue Ecancermedicalscience 2 2008 126
7. A. Albini, G. Pennesi, F. Donatelli, R. Cammarota, S. De Flora, and D.M. Noonan Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention J Natl Cancer Inst 102 1 2010 14 25
8. E.T. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 24 2009 2231 2247
9. R.E. Coleman, M.N. Maisey, R.K. Knight, and R.D. Rubens Mitoxantrone in advanced breast cancer - a phase II study with special attention to cardiotoxicity Eur J Cancer Clin Oncol 20 6 1984 771 776
10. V.B. Pai, and M.C. Nahata Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention Drug Saf 22 4 2000 263 302
11. J. Cerny, A. Hassan, C. Smith, and B. Piperdi Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen Clin Colorectal Cancer 8 1 2009 55 58
12. D. Lenihan, T. Suter, M. Brammer, C. Neate, G. Ross, and J. Baselga Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab Ann Oncol 23 3 2012 791 800
13. E.T. Yeh, A.T. Tong, and D.J. Lenihan et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management Circulation 109 25 2004 3122 3131
14. E.A. Perez, M. Koehler, J. Byrne, A.J. Preston, E. Rappold, and M.S. Ewer Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials Mayo Clin Proc 83 6 2008 679 686
15. T.F. Chu, M.A. Rupnick, and R. Kerkela et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 9604 2007 2011 2019
16. G. Di Lorenzo, R. Autorino, and G. Bruni et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis Ann Oncol 20 9 2009 1535 1542
17. M.L. Telli, R.M. Witteles, G.A. Fisher, and S. Srinivas Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann Oncol 19 9 2008 1613 1618
18. P.S. Hall, L.C. Harshman, S. Srinivas, and R.M. Witteles The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients JACC Heart Fail 1 1 2013 72 78
19. R.J. Motzer, T.E. Hutson, and D. Cella et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma N Engl J Med 369 8 2013 722 731
20. W.H. Kruit, K.J. Punt, and S.H. Goey et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon: an unexpectedly frequent complication Cancer 74 10 1994 2850 2856
21. N.B. Leighl, L.E. Raez, and B. Besse et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung J Thorac Oncol 5 7 2010 1054 1059
22. D.V. Do, Q.D. Nguyen, and D. Boyer et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 8 2012 1658 1665
23. M.S. Ewer, and S.M. Lippman Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity J Clin Oncol 23 13 2005 2900 2902
24. N. Fallah-Rad, M. Lytwyn, T. Fang, I. Kirkpatrick, and D.S. Jassal Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy J Cardiovasc Magn Reson 10 2008 5
25. D. Cardinale, A. Colombo, and G. Lamantia et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 3 2010 213 220
26. H. Sawaya, J.C. Plana, and M. Scherrer-Crosbie Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy Heart Fail Clin 7 3 2011 313 321
27. G. Curigliano, D. Cardinale, T. Suter ESMO Guidelines Working Group Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Ann Oncol 23 Suppl 7 2012 vii155 vii166
28. A. Seidman, C. Hudis, and M.K. Pierri et al. Cardiac dysfunction in the trastuzumab clinical trials experience J Clin Oncol 20 5 2002 1215 1221
29. G.M. Felker, R.E. Thompson, and J.M. Hare et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy N Engl J Med 342 15 2000 1077 1084
30. S. Stewart, K. MacIntyre, D.J. Hole, S. Capewell, and J.J. McMurray More 'malignant' than cancer? Five-year survival following a first admission for heart failure Eur J Heart Fail 3 3 2001 315 322
31. V.J. Ferrans Overview of cardiac pathology in relation to anthracycline cardiotoxicity Cancer Treat Rep 62 6 1978 955 961
32. K. Shan, A.M. Lincoff, and J.B. Young Anthracycline-induced cardiotoxicity Ann Intern Med 125 1 1996 47 58
33. G.J. Berry, and M. Jorden Pathology of radiation and anthracycline cardiotoxicity Pediatr Blood Cancer 44 7 2005 630 637
34. G. Minotti, G. Cairo, and E. Monti Role of iron in anthracycline cardiotoxicity: new tunes for an old song? [published correction appears in FASEB J. 1999;13(3):594] FASEB J 13 2 1999 199 212
35. D. Lebrecht, and U.A. Walker Role of mtDNA lesions in anthracycline cardiotoxicity Cardiovasc Toxicol 7 2 2007 108 113
36. J.M. Berthiaume, and K.B. Wallace Adriamycin-induced oxidative mitochondrial cardiotoxicity Cell Biol Toxicol 23 1 2007 15 25
37. B. Ky, P. Vejpongsa, E.T. Yeh, T. Force, and J.J. Moslehi Emerging paradigms in cardiomyopathies associated with cancer therapies Circ Res 113 6 2013 754 764
38. S. Zhang, X. Liu, and T. Bawa-Khalfe et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 18 11 2012 1639 1642
39. M. Katayama, Y. Imai, and H. Hashimoto et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy J Cardiol 54 2 2009 330 334
40. J.S. Gottdiener, F.R. Appelbaum, V.J. Ferrans, A. Deisseroth, and J. Ziegler Cardiotoxicity associated with high-dose cyclophosphamide therapy Arch Intern Med 141 6 1981 758 763
41. S. Hariharan, and S. Lowry Cardiotoxicity associated with sunitinib Lancet 371 9690 2008 1244 1245 author reply 1245
42. M.S. Ewer, and S.M. Ewer Cardiotoxicity of anticancer treatments: what the cardiologist needs to know Nat Rev Cardiol 7 10 2010 564 575
43. R. Kerkela, K.C. Woulfe, and J.B. Durand et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase Clin Transl Sci 2 1 2009 15 25
44. C.F. Greineder, S. Kohnstamm, and B. Ky Heart failure associated with sunitinib: lessons learned from animal models Curr Hypertens Rep 13 6 2011 436 441
45. K. Lemmens, K. Doggen, and G.W. De Keulenaer Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure Circulation 116 8 2007 954 960
46. S.A. Crone, Y.Y. Zhao, and L. Fan et al. ErbB2 is essential in the prevention of dilated cardiomyopathy Nat Med 8 5 2002 459 465
47. T.K. Choueiri, E.L. Mayer, and Y. Je et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab J Clin Oncol 29 6 2011 632 638
48. E.A. Hawkes, A.F. Okines, C. Plummer, and D. Cunningham Cardiotoxicity in patients treated with bevacizumab is potentially reversible J Clin Oncol 29 18 2011 e560 e562
49. F.J. Giordano, H.P. Gerber, and S.P. Williams et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function Proc Natl Acad Sci U S A 98 10 2001 5780 5785
50. J.D. Groarke, P.L. Nguyen, A. Nohria, R. Ferrari, S. Cheng, and J. Moslehi Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease Eur Heart J 35 10 2014 612 623
51. S.C. Darby, M. Ewertz, and P. McGale et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer N Engl J Med 368 11 2013 987 998
52. H.J. van der Pal, E.C. van Dalen, and E. van Delden et al. High risk of symptomatic cardiac events in childhood cancer survivors J Clin Oncol 30 13 2012 1429 1437
53. M. Tukenova, C. Guibout, and O. Oberlin et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer [published correction appears in J Clin Oncol. 2010;28(19):3205] J Clin Oncol 28 8 2010 1308 1315
54. W. Wu, A. Masri, and Z.B. Popovic et al. Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study Circulation 127 14 2013 1476 1485
55. D.A. Mulrooney, M.W. Yeazel, and T. Kawashima et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort BMJ 339 2009 b4606
56. J.R. Stewart, L.F. Fajardo, S.M. Gillette, and L.S. Constine Radiation injury to the heart Int J Radiat Oncol Biol Phys 31 5 1995 1205 1211
57. E.M. van Leeuwen-Segarceanu, W.J. Bos, and L.D. Dorresteijn et al. Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease Cancer Treat Rev 37 5 2011 391 403
58. P.J. Lee, and R. Mallik Cardiovascular effects of radiation therapy: practical approach to radiation therapy-induced heart disease Cardiol Rev 13 2 2005 80 86
59. J.P. Veinot, and W.D. Edwards Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases Hum Pathol 27 8 1996 766 773
60. I. Seemann, K. Gabriels, and N.L. Visser et al. Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature Radiother Oncol 103 2 2012 143 150
61. K.G. Ordovas, and C.B. Higgins Delayed contrast enhancement on MR images of myocardium: past, present, future Radiology 261 2 2011 358 374
62. M.J. Hooning, A. Botma, and B.M. Aleman et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer J Natl Cancer Inst 99 5 2007 365 375
63. K. Ylänen, T. Poutanen, P. Savikurki-Heikkilä, I. Rinta-Kiikka, A. Eerola, and K. Vettenranta Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer J Am Coll Cardiol 61 14 2013 1539 1547
64. K. Gabriels, S. Hoving, and I. Seemann et al. Local heart irradiation of ApoE(-/-) mice induces microvascular and endocardial damage and accelerates coronary atherosclerosis Radiother Oncol 105 3 2012 358 364
65. S. Hoving, S. Heeneman, and M.J. Gijbels et al. Irradiation induces different inflammatory and thrombotic responses in carotid arteries of wildtype C57BL/6J and atherosclerosis-prone ApoE(-/-) mice Radiother Oncol 105 3 2012 365 370
66. F.A. Stewart, S. Heeneman, and J. Te Poele et al. Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage Am J Pathol 168 2 2006 649 658
67. D. O H-Icí, and J. Garot Radiation-induced heart disease Circ Heart Fail 4 1 2011 e1 e2
68. E.S. Koh, T.H. Tran, and M. Heydarian et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk Radiat Oncol 2 2007 13
69. L.B. Marks, X. Yu, and R.G. Prosnitz et al. The incidence and functional consequences of RT-associated cardiac perfusion defects Int J Radiat Oncol Biol Phys 63 1 2005 214 223
70. Z. Barjaktarovic, A. Shyla, and O. Azimzadeh et al. Ionising radiation induces persistent alterations in the cardiac mitochondrial function of C57BL/6 mice 40 weeks after local heart exposure Radiother Oncol 106 3 2013 404 410
71. E. Yu, P.A. Calvert, and J.R. Mercer et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans Circulation 128 7 2013 702 712
72. J. Herrmann, L.O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman Angiogenesis in atherogenesis Arterioscler Thromb Vasc Biol 26 9 2006 1948 1957
73. N.L. Weintraub, W.K. Jones, and D. Manka Understanding radiation-induced vascular disease J Am Coll Cardiol 55 12 2010 1237 1239
74. M. Halle, P. Hall, and P. Tornvall Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B J Intern Med 269 5 2011 469 477
75. M. Mahmoudi, J. Mercer, and M. Bennett DNA damage and repair in atherosclerosis Cardiovasc Res 71 2 2006 259 268
76. M. Lotrionte, G. Biondi-Zoccai, and A. Abbate et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity Am J Cardiol 112 12 2013 1980 1984
77. R.G. Schwartz, D. Jain, and E. Storozynsky Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively J Nucl Cardiol 20 3 2013 443 464
78. B.W. Choi, H.J. Berger, and P.E. Schwartz et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance Am Heart J 106 4 Pt 1 1983 638 643
79. J. Alexander, N. Dainiak, and H.J. Berger et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography N Engl J Med 300 6 1979 278 283
80. R.G. Schwartz, W.B. McKenzie, and J. Alexander et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography Am J Med 82 6 1987 1109 1118
81. R. Hoffmann, G. Barletta, and S. von Bardeleben et al. Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography J Am Soc Echocardiogr 27 3 2014 292 301
82. P. Thavendiranathan, A.D. Grant, T. Negishi, J.C. Plana, Z.B. Popović, and T.H. Marwick Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy J Am Coll Cardiol 61 1 2013 77 84
83. V. Eder, S. Hérault, and C. Hudelo et al. Evaluation of left ventricular systolic function by 3D echocardiography: a comparative study with X-ray angiography and radionuclide angiography Eur J Ultrasound 11 2 2000 105 115
84. N.G. Bellenger, M.I. Burgess, and S.G. Ray et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance: are they interchangeable? Eur Heart J 21 6 2000 1387 1396
85. N.M. Fine, C.S. Crowson, G. Lin, J.K. Oh, H.R. Villarraga, and S.E. Gabriel Evaluation of myocardial function in patients with rheumatoid arthritis using strain imaging by speckle-tracking echocardiography Ann Rheum Dis 2013 http://dx.doi.org/10.1136/annrheumdis-2013-203314 Epub ahead of print
86. H. Sawaya, I.A. Sebag, and J.C. Plana et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab Circ Cardiovasc Imaging 5 5 2012 596 603
87. J.T. Poterucha, S. Kutty, R.K. Lindquist, L. Li, and B.W. Eidem Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction J Am Soc Echocardiogr 25 7 2012 733 740
88. N. Fallah-Rad, J.R. Walker, and A. Wassef et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy J Am Coll Cardiol 57 22 2011 2263 2270
89. Xu YH J, Pellikka P, Ansell S, Cha S, Early changes in 2D-speckle tracking echocardiography may predict a decrease in left ventricular ejection fraction in lymphoma patients undergoing anthracycline chemotherapy. J Am Soc Echocardiogr. 2013;26(6):B52.
90. P.W. Stoodley, D.A. Richards, and R. Hui et al. Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy Eur J Echocardiogr 12 12 2011 945 952
91. T. Nousiainen, E. Jantunen, E. Vanninen, and J. Hartikainen Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients Br J Cancer 86 11 2002 1697 1700
92. D. Cardinale, M.T. Sandri, and A. Martinoni et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy J Am Coll Cardiol 36 2 2000 517 522
93. B. Ky, M. Putt, and H. Sawaya et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab J Am Coll Cardiol 63 8 2014 809 816
94. Y. Kang, X. Xu, and L. Cheng et al. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy Eur J Heart Fail 16 3 2014 300 308
95. D. Cardinale, A. Colombo, and R. Torrisi et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 25 2010 3910 3916
96. P. Lancellotti, V.T. Nkomo, L.P. Badano European Society of Cardiology Working Groups on Nuclear Cardiology and Cardiac Computed Tomography and Cardiovascular Magnetic Resonance; American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography [published correction appears in J Am Soc Echocardiogr. 2013;26(11):1305. Bergler, Jutta [corrected to Bergler-Klein, Jutta]] J Am Soc Echocardiogr 26 9 2013 1013 1032
97. P.A. Heidenreich, I. Schnittger, and H.W. Strauss et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease [published correction appears in J Clin Oncol. 2007;25(12):1635] J Clin Oncol 25 1 2007 43 49
98. C.R. Correa, H.I. Litt, W.T. Hwang, V.A. Ferrari, L.J. Solin, and E.E. Harris Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer J Clin Oncol 25 21 2007 3031 3037
99. T.M. Zagar, and L.B. Marks Breast cancer radiotherapy and coronary artery stenosis: location, location, location J Clin Oncol 30 4 2012 350 352
100. M. Kruk, D. Noll, and S. Achenbach et al. Impact of coronary artery calcium characteristics on accuracy of CT Angiography JACC Cardiovasc Imaging 7 1 2014 49 58
101. C.E. Rochitte, R.T. George, and M.Y. Chen et al. Computed tomography angiography and perfusion to assess coronary artery stenosis causing perfusion defects by single photon emission computed tomography: the CORE320 study Eur Heart J 35 17 2014 1120 1130
102. M.J. Adams, S.R. Lipsitz, and S.D. Colan et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy J Clin Oncol 22 15 2004 3139 3148
103. M. Jarfelt, V. Kujacic, D. Holmgren, R. Bjarnason, and B. Lannering Exercise echocardiography reveals subclinical cardiac dysfunction in young adult survivors of childhood acute lymphoblastic leukemia Pediatr Blood Cancer 49 6 2007 835 840
104. C.W. Yancy, M. Jessup, B. Bozkurt American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 16 2013 e147 e239
105. B.V. Jensen, T. Skovsgaard, and S.L. Nielsen Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients Ann Oncol 13 5 2002 699 709
106. M. Martín, F.J. Esteva, and E. Alba et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations Oncologist 14 1 2009 1 11
107. M. Schweiger, H. Dave, and F. Lemme et al. Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child ASAIO J 59 5 2013 520 522
108. G.H. Oliveira, M. Dupont, and D. Naftel et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry J Am Coll Cardiol 63 3 2014 240 248
109. C. Kurihara, T. Nishimura, and K. Nawata et al. Successful bridge to recovery with VAD implantation for anthracycline-induced cardiomyopathy J Artif Organs 14 3 2011 249 252
110. S.E. Lipshultz, S.R. Lipsitz, and S.M. Mone et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer N Engl J Med 332 26 1995 1738 1743
111. S.E. Lipshultz, S.D. Colan, R.D. Gelber, A.R. Perez-Atayde, S.E. Sallan, and S.P. Sanders Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 324 12 1991 808 815
112. S.E. Lipshultz, S.R. Lipsitz, and S.E. Sallan et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia J Clin Oncol 23 12 2005 2629 2636
113. J.H. Silber Role of afterload reduction in the prevention of late anthracycline cardiomyopathy Pediatr Blood Cancer 44 7 2005 607 613
114. M.S. Ewer, M.T. Vooletich, and J.B. Durand et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 31 2005 7820 7826
115. C.L. Arteaga, M.X. Sliwkowski, C.K. Osborne, E.A. Perez, F. Puglisi, and L. Gianni Treatment of HER2-positive breast cancer: current status and future perspectives Nat Rev Clin Oncol 9 1 2012 16 32
116. A. Goldhirsch, R.D. Gelber, M.J. Piccart-Gebhart Herceptin Adjuvant (HERA) Trial Study Team 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Lancet 382 9897 2013 1021 1028
117. S.M. Swain, S.B. Kim, and J. Cortés et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 14 6 2013 461 471
118. Y. Kureishi, Z. Luo, and I. Shiojima et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals [published correction appears in Nat Med. 2001;7(1):129] Nat Med 6 9 2000 1004 1010
119. L. Ma, R. Gul, and J. Habibi et al. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat Am J Physiol Heart Circ Physiol 302 11 2012 H2341 H2351
120. S. Hoving, S. Heeneman, and M.J. Gijbels et al. Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice Radiother Oncol 101 1 2011 100 108
121. F. Santoro, R. Ieva, and P. Lupo et al. Late calcification of the mitral-aortic junction causing transient complete atrio-ventricular block after mediastinal radiation of Hodgkin lymphoma: multimodal visualization Int J Cardiol 155 3 2012 e49 e50
122. E.C. van Dalen, H.N. Caron, H.O. Dickinson, and L.C. Kremer Cardioprotective interventions for cancer patients receiving anthracyclines Cochrane Database Syst Rev 6 2011 CD003917
123. S. Seicean, A. Seicean, J.C. Plana, G.T. Budd, and T.H. Marwick Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study J Am Coll Cardiol 60 23 2012 2384 2390
124. S. Seicean, A. Seicean, N. Alan, J.C. Plana, G.T. Budd, and T.H. Marwick Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure Circ Heart Fail 6 3 2013 420 426
125. N. Kalay, E. Basar, and I. Ozdogru et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 11 2006 2258 2262
126. N.A. El-Shitany, O.A. Tolba, M.R. El-Shanshory, and E.E. El-Hawary Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia J Card Fail 18 8 2012 607 613
127. A. Elitok, F. Oz, and A.Y. Cizgici et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with 6-month follow-up Cardiol J 2014 http://dx.doi.org/10.5603/CJ.a2013.0150 Epub ahead of print
128. M.G. Kaya, M. Ozkan, and O. Gunebakmaz et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 167 5 2013 2306 2310
129. P. Georgakopoulos, P. Roussou, and E. Matsakas et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up Am J Hematol 85 11 2010 894 896
130. X. Bosch, M. Rovira, and M. Sitges et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies) J Am Coll Cardiol 61 23 2013 2355 2362
131. J.H. Silber, A. Cnaan, and B.J. Clark et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines J Clin Oncol 22 5 2004 820 828
132. D. Cardinale, A. Colombo, and M.T. Sandri et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 23 2006 2474 2481
133. H. Nakamae, K. Tsumura, and Y. Terada et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone Cancer 104 11 2005 2492 2498
134. M. Dessi, A. Piras, and C. Madeddu et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction Exp Therap Med 2 5 2011 1003 1009
135. Z. Acar, A. Kale, and M. Turgut et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy J Am Coll Cardiol 58 9 2011 988 989
136. J.Y. Choe, A.B. Combs, and K. Folkers Potentiation of the toxicity of adriamycin by propranolol Res Commun Chem Pathol Pharmacol 21 3 1978 577 580
137. D. Bernstein, G. Fajardo, and M. Zhao et al. Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes Am J Physiol Heart Circ Physiol 289 6 2005 H2441 H2449